TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03198455

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agaricus blazei Murill-based mushroom extract, Andosan™
Description: Dietary Supplement: Agaricus blazei Murill-based mushroom extract, Andosan™

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drinking water with food coloring and salt
Study: NCT00003136

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT01007071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Growth Hormone (1-134)
Description: Subjects randomized to human growth hormone (1-134) for 16 weeks. In this arm, growth hormone is dosed sc on a daily basis and increased over first 6 weeks (Men: start at 0.2 mg sc/d, increase to 0.6 mg sc/d after 4 weeks. Women, postmenopausal: start at 0.3 mg sc/d, increase to 0.9 mg sc/d after 4 weeks. Women premenopausal or on estrogen: start at 0.6 mg sc/d, increase to 1.3 mg sc/d after 4 weeks.) Dose adjustments based on serum IGF-1 levels at 6 and 12 weeks, with final IGF-1 measurement for efficacy performed at 16 weeks, with goal in range of -0.5 SD to +2SD. An elevated serum IGF-1 value will result in a 20% dose reduction in GH in an active and random placebo patient. Similarly, a low serum IGF-1 will result in a 20% dose increase in an active and random placebo subject.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo
Study: NCT03423108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: G150
Description: This group will receive 150 min/week of combined exercise training, structured and supervised.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: G300
Description: This group will receive 300 min/week of combined exercise training, structured and supervised.
Study: NCT03094078

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: News item with spin
Description: Interpretation of news item with spin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: News item without spin
Description: Interpretation of news item without spin
Study: NCT03516227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: heart rate variability biofeedback
Description: The HRVBF group received four, one-on-one bedside biofeedback training sessions (20-minutes a day for 4 days), and practiced on their own (10-minutes twice a day) using a FDA-regulated, hand-held mobile biofeedback device (StressEraser, Helico Inc., New York, NY, USA).26 The control group received usual care.Afterwards, all participants were telephoned bi-weekly and encouraged to practice slow breathing (HRVBF group) or to perform self-care (control group) for three months.
Study: NCT02055872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous albumin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT01658137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prudent Diet
Description: This intervention lasts 2 weeks (14 days).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Typical Western Diet
Description: This intervention lasts 2 weeks (14 days).
Study: NCT01011803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined speech therapy tools, measures of swallowing function
Description: All subjects will be assessed using combined speech therapy tools and ordinal measures of swallowing function. The combined speech therapy tools were \[diadochokinesis, glottal coup, and the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)\]. The ordinal measures of swallowing function included Dysphagia Admission Screening Tool (DAST), Modified Barium Swallow (MBS), and Fiberoptic Endoscopic Evaluation of the Swallow (FEES).
Study: NCT04031274

Intervention type: DEVICE
Intervention: TAVI
Description: Trascatheter aortic valve implantation

Intervention type: DEVICE
Intervention: TAVI
Description: Trascatheter aortic valve implantation

Intervention type: DEVICE
Intervention: TAVI
Description: Trascatheter aortic valve implantation
Study: NCT02548091

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples for assays of plasma inflammatory markers (cytokines InterLeukin-6, InterLeukin-8, InterLeukin-10)
Description: The same amount of blood sample is collected from both arms of study at the same time of the procedure.~In each patient, in the per procedure period, a total of 50 milliliters of blood sample is drawn from the pulmonary circulation downstream and upstream of obstructive lesion, the trunk of pulmonary artery, the superior vena cava and the femoral arterial line prior to angioplasty and at the end of procedure; in the post interventional care unit 10 milliliters of blood sample will be draw daily from the superior vena cava catheter line and femoral arterial line.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples for assays of plasma inflammatory markers (cytokines InterLeukin-6, InterLeukin-8, InterLeukin-10)
Description: The same amount of blood sample is collected from both arms of study at the same time of the procedure.~In each patient, in the per procedure period, a total of 50 milliliters of blood sample is drawn from the pulmonary circulation downstream and upstream of obstructive lesion, the trunk of pulmonary artery, the superior vena cava and the femoral arterial line prior to angioplasty and at the end of procedure; in the post interventional care unit 10 milliliters of blood sample will be draw daily from the superior vena cava catheter line and femoral arterial line.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non invasive ventilation
Study: NCT03600974

Intervention type: PROCEDURE
Intervention: Stretta
Description: Stretta for Endoscopy-E(+),Acid-A(+),Reflux-symptom association-S(+) or lower oesophageal sphincter-L(+) group

Intervention type: PROCEDURE
Intervention: Stretta
Description: Stretta for Endoscopy-E(+),Acid-A(+),Reflux-symptom association-S(+) or lower oesophageal sphincter-L(+) group
Study: NCT02548091

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: monitoring system Pulse-Induced Contour Cardiac Output (Picco)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: monitoring system Pulse-Induced Contour Cardiac Output (Picco)
Study: NCT04031274

Intervention type: DEVICE
Intervention: TMVR/r
Description: Transcatheter mitral valve replacement/repair
Study: NCT03221790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low FODMAP Diet followed by a High FODMAP Diet
Description: 3 weeks on a low FODMAP diet followed by 3 weeks on a high FODMAP Diet
Study: NCT01549535

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system
Description: endoscopic diagnosis, treatment and video observation of the digestive tract, endoscopy and endoscopic treatment within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) of adults patients
Study: NCT03734978

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis
Description: biochemistry

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis
Description: biochemistry

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis
Description: biochemistry

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis
Description: biochemistry
Study: NCT01691677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days
Study: NCT03600974

Intervention type: PROCEDURE
Intervention: Laparoscopic Nissen fundoplication
Description: Laparoscopic Nissen fundoplication for E(+),A(+) or L(+) group
Study: NCT01691677

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days
Study: NCT01778374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No participant choice of counselor
Description: Participants in this arm of the study are randomized to an interactive video counselor with no choice of counselor. This is delivered via a touchscreen tablet device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participant choice of counselor
Description: Participants in this arm of the study are randomized to an interactive video counselor with a choice of four different counselors. These gender and ethnically diverse counselors are delivered via a touchscreen tablet device.
Study: NCT04405544

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT-scan
Description: chest CT-scan

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT-scan
Description: chest CT-scan

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EEG
Description: Electroencephalography

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EEG
Description: Electroencephalography

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EP
Description: Evoked potential

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EP
Description: Evoked potential

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pulse oximetry
Description: Pulse oximetry

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pulse oximetry
Description: Pulse oximetry

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood tests
Description: Blood tests

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood tests
Description: Blood tests
Study: NCT04422561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Tablets
Description: two doses 72 hours apart
Study: NCT03600974

Intervention type: PROCEDURE
Intervention: Laparoscopic Nissen fundoplication
Description: Laparoscopic Nissen fundoplication for E(+),A(+) or L(+) group

Intervention type: PROCEDURE
Intervention: Laparoscopic Nissen fundoplication
Description: Laparoscopic Nissen fundoplication for E(+),A(+) or L(+) group

Intervention type: DRUG
Intervention: Probiotic Agent
Description: Probiotic Agent for I(+)G/W；Live Bacillus Licheniformis Cranules 0.5g bid； Bifidbacterium 0.63g bid

Intervention type: DRUG
Intervention: PPI
Description: PPIs for A(+),E(+)or S(+) patients: Nexium 20mg Qd/Bid;Lansoprazole 30mg Qd/Bid；omeprazole 10mg-30mg Qd-Bid;Rabeprazole 10mg Qd/Bid;Esomeprazole 20mg Qd/Bid;Pantoprazole 40mg Qd/Bid

Intervention type: DRUG
Intervention: PPI
Description: PPIs for A(+),E(+)or S(+) patients: Nexium 20mg Qd/Bid;Lansoprazole 30mg Qd/Bid；omeprazole 10mg-30mg Qd-Bid;Rabeprazole 10mg Qd/Bid;Esomeprazole 20mg Qd/Bid;Pantoprazole 40mg Qd/Bid

Intervention type: DRUG
Intervention: PPI
Description: PPIs for A(+),E(+)or S(+) patients: Nexium 20mg Qd/Bid;Lansoprazole 30mg Qd/Bid；omeprazole 10mg-30mg Qd-Bid;Rabeprazole 10mg Qd/Bid;Esomeprazole 20mg Qd/Bid;Pantoprazole 40mg Qd/Bid

Intervention type: DRUG
Intervention: Prokinetic Motility Agents
Description: Prokinetic Motility Agents for M(+) group; Mosapride 5mg Tid; Domperidone 10mg Tid
Study: NCT00336791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: FEC Chemotherapy: 500 mg/m\^2 IV on day 1 of 21 day cycle.~FAC Chemotherapy: 500 mg/m\^2 IV on day 1 and day 4 of 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: FEC Chemotherapy: 500 mg/m\^2 IV on day 1 of 21 day cycle.~FAC Chemotherapy: 500 mg/m\^2 IV on day 1 and day 4 of 21 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: FAC and FEC Chemotherapy:~500 mg/m\^2 IV on day 1 of 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: FAC and FEC Chemotherapy:~500 mg/m\^2 IV on day 1 of 21 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: FAC Chemotherapy: 50 mg/m\^2 IV on day 1 over 72 hour continuous infusion or IV bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: FAC Chemotherapy: 50 mg/m\^2 IV on day 1 over 72 hour continuous infusion or IV bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 by vein (IVPB) over 1 hour every week for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: FEC: 100 mg/m\^2 IV on day 1 of 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: FEC: 100 mg/m\^2 IV on day 1 of 21 day cycle.
Study: NCT01267552

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non drains will be placed during operation
Description: Non drains will be placed during operation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed suction drainage
Description: Closed suction drainage will be placed during operation
Study: NCT02334215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Description: Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
Study: NCT03014037

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Unilateral Bone Marrow Procurement
Description: A total of 61cc of bone marrow will be procured under ultrasound guidance from one posterior superior iliac spine (PSIS) via 3 passes, each at least 1 cm apart, through the bone cortex. In each pass, investigators will obtain 2.3cc of BMA with a 60cc syringes.
Study: NCT02548091

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Computed tomography (CT)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed tomography (CT)
Study: NCT02971449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amazon Fire Tablet
Description: A generic amazon fire tablet with pre-loaded instructional videos

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICCM Traditional Trainins
Description: Standard, Didactic VHT Training intervention as an active comparator
Study: NCT04016506

Intervention type: OTHER
Intervention: nutritional questionnaire
Description: nutritional questionnaire is given to the patient after the injury
Study: NCT00646347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional upper limb stroke rehabilitation
Description: Patient will be given a ten weeks conventional upper limb therapy. 3 sessions will be provided weekly in the first 4 weeks and 2 therapy sessions will be provided weekly in the subsequent 6 weeks. Patients will receive half an hour of conventional therapy in each session.~Patient will be taught to carry out two and half hours conventional self practice exercise daily for a period of ten weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuro Hand Orthosis Program (NHOP)
Description: The NHO is based on a design of dynamic hand orthosis for orthopaedic patients after hand surgery. We use it to support CVA patient's wrist and finger to perform grasping to transport an object (ball) from place to place to achieve the follows;~1. NHO can assist stroke patients to experience successful hand grasping with an object and produce voluntary movement from their paralytic arm. This successful experience will positively reinforce the patient to continue to use their paralytic arm and change the patient's behavior and perception in the arm usage.~2. The NHO Program is able to engage patients to perform their exercises and activities by themselves independently with the effect of intensive therapy.~The intervention (NHOP) group will receive same treatment intensity as the control group but with a Neuro Hand Orthosis.
Study: NCT03529734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 min running
Description: This was already explained in the description of arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local strengthening exercises
Description: This was already explained in the description of arm
Study: NCT04918069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Topical capsaicin ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical placebo ointment
Study: NCT00859716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE393
Description: ACE393 250 micrograms as intra muscular injection at day 0 and day 21

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaccine
Description: Placebo 500 micrograms Alhydrogel as intra muscular injection at day 0 and day 21
Study: NCT02504957

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Photodynamic therapy using polyhematoporphyrin
Study: NCT02858596

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Semi-solid feed (Terumo PG soft)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Liquid feed (Meibalance)
Study: NCT01410669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Description: MI is a client-centered counseling approach developed to deliver stage-tailored intervention messages using non-confrontational, supportive communication strategies. The client is encouraged to explore the barriers and facilitating factors associated with the behavior change. The interviewer's role is to guide the conversation and avoid use of conventional directive approaches (e.g., persuasion, providing information).~In this trial, a trained motivational interviewer meets individually with patients randomized to the intervention for one-hour at baseline, followed by four MI telephone follow up contacts at 1-, 2-, and 4-months post baseline.
Study: NCT02998905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOAC
Description: Apixaban or dabigatran or edoxaban or rivaroxaban at recommended dosing for stroke prevention in atrial fibrillation. The particular agent is at the discretion of the local investigator.
Study: NCT02583828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 50mg
Study: NCT02998905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic Acid
Description: Acetylsalicylic acid 81 mg/day
Study: NCT01244789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin and paclitaxel
Description: 6 courses of iv 3-weekly chemotherapy Carboplatin AUC5 Paclitaxel 175mg/m2

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: observation
Description: active observation
Study: NCT03482284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Participants receive different monosaccharides for a defined number of days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Participants receive different monosaccharides for a defined number of days.
Study: NCT04171180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide/formoterol
Description: apply different dosage of budesonide/formoterol in two groups and evaluate the treatment effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol
Description: apply different dosage of budesonide/formoterol in two groups and evaluate the treatment effects.
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training for Dysregulated Eating
Description: Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).
Study: NCT03014037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Bone Marrow Procurement
Description: 30.5cc of bone marrow will be obtained under ultrasound guidance from each posterior superior iliac spine (PSIS) with 3 passes, at least 1 cm apart, per side (10.17cc per pass) using 60cc syringes. The collection from each PSIS will be combined to yield a total of 61cc.
Study: NCT03600974

Intervention type: DRUG
Intervention: Neuromodulators
Description: Neuromodulators for P(+) or S(+);Flupentixol and Melitracen 1# bid;

Intervention type: DRUG
Intervention: Neuromodulators
Description: Neuromodulators for P(+) or S(+);Flupentixol and Melitracen 1# bid;
Study: NCT01907880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pamidronate
Description: 90mg IV once every 4 weeks for 3 cycles
Study: NCT02442622

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational therapy
Description: Occupational therapy for de Quervain's Tenosynovitis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occupational therapy with ASTYM
Description: Occupational therapy for de Quervain's Tenosynovitis plus ASTYM
Study: NCT03991416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Understanding Your Baby
Description: Research-based knowledge on the understanding and meeting of the baby's socioemotional needs is delivered to the parents systematically by public health visitors based on a manual, cue cards, and video clips at four time points from 1 to 10 months postpartum.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postnatal care as usual
Description: In accordance with Danish national guidelines, health visitors visit families during the infants first year of life, where they weigh and measure the infant. Further, they offer individual guidance and support regarding for instance feeding, sleeping, how to stimulate the infant, and the developmental stages that the infant goes through.
Study: NCT01907880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: 4mg IV every 4 weeks for 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study: NCT03625791

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: 1 tube with 4 ml of blood per patient

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: 1 tube with 4 ml of blood per patient